Engineers Gate Manager LP Sells 254,496 Shares of Elanco Animal Health Incorporated $ELAN

Engineers Gate Manager LP lessened its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 75.2% during the second quarter, HoldingsChannel.com reports. The firm owned 83,722 shares of the company’s stock after selling 254,496 shares during the period. Engineers Gate Manager LP’s holdings in Elanco Animal Health were worth $2,060,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in ELAN. BlackRock Inc. bought a new stake in Elanco Animal Health during the 2nd quarter worth about $1,202,198,000. Primecap Management Co. CA acquired a new position in shares of Elanco Animal Health during the 2nd quarter worth about $1,118,402,000. T. Rowe Price Investment Management Inc. grew its holdings in shares of Elanco Animal Health by 11.8% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company’s stock valued at $797,197,000 after acquiring an additional 3,717,404 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Elanco Animal Health by 7.3% in the 4th quarter. Geode Capital Management LLC now owns 9,425,533 shares of the company’s stock valued at $213,343,000 after acquiring an additional 640,098 shares in the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Elanco Animal Health in the second quarter valued at about $205,636,000. Institutional investors and hedge funds own 97.48% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on the company. TD Cowen upped their target price on Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, June 18th. Piper Sandler reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, June 29th. UBS Group increased their price objective on Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Weiss Ratings upgraded shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, September 4th. Finally, KeyCorp upped their price target on shares of Elanco Animal Health from $29.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $29.09.

Elanco Animal Health Trading Down 0.5%

Shares of Elanco Animal Health stock opened at $23.02 on Wednesday. The business has a fifty day simple moving average of $24.47 and a two-hundred day simple moving average of $23.87. Elanco Animal Health Incorporated has a 1 year low of $18.22 and a 1 year high of $27.98. The company has a market capitalization of $11.50 billion, a price-to-earnings ratio of -56.16, a P/E/G ratio of 1.72 and a beta of 1.68. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.27 by $0.07. The firm had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The company’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Research analysts forecast that Elanco Animal Health Incorporated will post 1.13 EPS for the current year.

Insider Buying and Selling at Elanco Animal Health

In related news, Director Paul Herendeen acquired 10,000 shares of the business’s stock in a transaction on Friday, August 7th. The stock was purchased at an average cost of $23.68 per share, for a total transaction of $236,800.00. Following the completion of the transaction, the director directly owned 111,687 shares of the company’s stock, valued at approximately $2,644,748.16. The trade was a 9.83% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Shiv O’Neill acquired 3,998 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were bought at an average price of $23.58 per share, with a total value of $94,272.84. Following the completion of the transaction, the insider directly owned 87,832 shares of the company’s stock, valued at approximately $2,071,078.56. The trade was a 4.77% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 63,198 shares of company stock worth $1,473,109 in the last ninety days. Insiders own 1.14% of the company’s stock.

Elanco Animal Health Profile

Elanco Animal Health Incorporated (NYSE: ELAN) is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites, improve animal well-being and support productivity in livestock and aquaculture.

The company’s products include vaccines, parasiticides, antibiotics, animal health pharmaceuticals and nutritional supplements. Its companion animal portfolio serves dogs and cats, while its livestock business provides products for cattle, poultry, swine and aquaculture operations.